Allogene Therapeutics

(NASDAQ) ALLO

Current Price$1.81

Market Cap$617.83M

Since IPO (2018)-93%

5 Year-92%

1 Year+44%

1 Month-9%

Allogene Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 1.79	2026-07-17

Allogene Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-10.5%	USD 2.00	2026-07-10
1 month	-8.67%	USD 1.96	2026-06-17
3 month	-25.1%	USD 2.39	2026-04-17
Year to date	+30.66%	USD 1.37	2025-12-31
1 year	+44.35%	USD 1.24	2025-07-17
3 year	-66.35%	USD 5.32	2023-07-18
5 year	-92.09%	USD 22.63	2021-07-16
Since inception	-92.84%	USD 25.00	2018-10-11

Allogene Therapeutics Financials at a Glance

Market Cap

$617.83M

Revenue (TTM)

$0.00

Net Income (TTM)

-$173.76M

EPS (TTM)

-$0.77

P/E Ratio

-2.33

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.81

Volume

4,939,744.406

Open

$1.75

Price

$1.81

Volume

4,939,744.406

Open

$1.75

Previous Close

$1.79

Daily Range

$1.74 - $1.83

52-Week Range

$0.98 - $4.46

Estimated Earnings Date

Aug 12, 2026

Dividend

$0.00

Beta (Volatility)

1.68 (High)

Price

$1.81

Volume

4,939,744.406

Open

$1.75

Previous Close

$1.79

Daily Range

$1.74 - $1.83

52-Week Range

$0.98 - $4.46

Estimated Earnings Date

Aug 12, 2026

ALLO News

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

Jason HawthorneOct 15, 2021

Worried businessman working in office with his coworker and having problems

Why Allogene Therapeutics Stock Is Getting Hammered Today

George Budwell, PhDOct 8, 2021

4 Companies That Could Upend the Pharma Industry

James HalleyJul 29, 2020

Here's Why Allogene Therapeutics Is Roaring Higher Today

Maxx ChatskoMay 14, 2020

2 Big Biotech Stock Upgrades: Can They Reach These Targets?

Cory RenauerMay 5, 2019

ALLO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Allogene Therapeutics

Allogene makes cancer treatments using healthy donor cells. These therapies help patients receive medicine much faster. The company aims to treat blood cancers and autoimmune diseases.

Off-the-Shelf T-Cell Therapies

Cemacabtagene ansegedleucel (cema-cel): Allogeneic T-cell therapy targeting proteins on cancer cells; serves patients with large B-cell lymphoma.
ALLO-329: Dual-targeting therapy for autoimmune diseases like lupus; designed to work with minimal or no chemotherapy.
ALLO-316: Investigational therapy targeting specific proteins on solid tumors; focused on treating advanced kidney cancer.
Dagger Technology: Proprietary engineering tool; helps the body accept donor cells by removing immune cells that cause rejection.

Key Moves and Strategic Shifts

Restructured a development agreement with Servier in May 2024 to regain control of several cancer-fighting product candidates.
Collaborated with Foresight Diagnostics, a division of Natera, to use specialized blood tests in clinical trials.
Licensed gene-editing technology from Arbor Biotechnologies to develop new treatments for various autoimmune conditions.
Initiated the RESOLUTION trial in 2025 to test therapies for patients with lupus and muscle inflammation.
Utilized its internal Cell Forge 1 facility in California to manufacture experimental cell products for clinical studies.

What Makes Allogene Different?

The company uses cells from healthy donors rather than the patients themselves. This allows for mass-produced batches that are ready for immediate use without waiting weeks for manufacturing.

Tracking the Financial Progress

Revenue remained at $0 in Q4 2025, which was unchanged from the same period in 2024.
Net loss reached $38.8 million in Q4 2025, narrowing by 35.3% from the $59.9 million loss in Q4 2024.
Free cash flow was negative $27.6 million in Q4 2025, an improvement from negative $37 million in Q4 2024.
Market capitalization was $302.3 million in Q4 2025, down 32.6% from $448.5 million in Q4 2024.

Bottom Line

Allogene is shifting from a research startup to a clinical-stage firm targeting large-scale cell therapy markets. Its move into autoimmune disease and first-line cancer treatments reflects an evolving strategy to improve patient access.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

152

CEO

David D. Chang, MD, PhD

Website

www.allogene.com

Headquarters

South San Francisco, CA 94080, US

ALLO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-56.45%

Return on Capital

-55.07%

Return on Assets

-43.88%

Earnings Yield

-42.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$617.83M

Shares Outstanding

345.15M

Volume

4.94M

Avg. Volume

8.35M

Financials (TTM)

Gross Profit

-$77.25M

Operating Income

-$190.22M

EBITDA

-$160.41M

Operating Cash Flow

-$109.23M

Capital Expenditure

-$296.00K

Free Cash Flow

-$109.53M

Cash & ST Invst.

$266.89M

Total Debt

$81.05M

Allogene Therapeutics Performance Analysis

Allogene Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 156,000	-99.9%
2023	2023-12-31	USD 95,000	-39.1%
2024	2024-12-31	USD 22,000	-76.8%
2025	2025-12-31	USD 0	N/A

Allogene Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Allogene Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.38	77.4%
2023	2023-12-31	USD -2.09	-12.3%
2024	2024-12-31	USD -1.32	-36.6%
2025	2025-12-31	USD -0.87	-34.6%

Allogene Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	17.9%
Q3	2025-09-30	17.4%
Q4	2025-12-31	10.5%
Q1	2026-03-31	-5.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$2.87M

+7.4%

Gross Margin

0.00%

N/A

Market Cap

$617.83M

N/A

Market Cap/Employee

$4.06M

N/A

Employees

152

N/A

Net Income

-$42.61M

+28.7%

EBITDA

-$39.44M

+30.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$266.89M

-4.7%

Total Debt

$81.05M

-0.3%

Accounts Receivable

$1.30M

N/A

Inventory

$0.00

N/A

Long Term Debt

$72.63M

-10.7%

Short Term Debt

$8.42M

N/A

Return on Assets

-43.88%

N/A

Return on Invested Capital

-51.74%

N/A

Free Cash Flow

-$12.92M

+75.6%

Operating Cash Flow

-$12.91M

+75.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ACHVAchieve Life Sciences, Inc.

ACHVAchieve Life Sciences, Inc.$6.27+5.20%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$2.83+5.99%

AVIRAtea Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.$4.87+3.29%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$5.44-0.18%

KYTXKyverna Therapeutics, Inc.

KYTXKyverna Therapeutics, Inc.$7.45+0.13%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$2.98+3.47%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.17+4.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98-0.04%

NFLXNetflix

NFLXNetflix$68.95-0.07%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.28-0.00%

Questions About ALLO

What is the current price of Allogene Therapeutics?

Allogene Therapeutics is trading at $1.79 per share.

What is the 52-week range for Allogene Therapeutics?

Over the past 52 weeks, Allogene Therapeutics has traded between $0.98 and $4.46.

How much debt does Allogene Therapeutics have?

As of the most recent reporting period, Allogene Therapeutics reported total debt of $81.05M.

How much cash does Allogene Therapeutics have on hand?

Allogene Therapeutics reported $30.31M in cash and cash equivalents in its most recent financial results.

What is Allogene Therapeutics’s dividend yield?

Allogene Therapeutics does not currently have a dividend yield.

Allogene Therapeutics

Allogene Therapeutics Financials at a Glance

ALLO News

Allogene Q2 Cash Tops $300 Million

Allogene Narrows Loss in Fiscal Q2

Why Beam Therapeutics Stock Dipped Today

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

Why Allogene Therapeutics Stock Is Getting Hammered Today

4 Companies That Could Upend the Pharma Industry

Here's Why Allogene Therapeutics Is Roaring Higher Today

2 Big Biotech Stock Upgrades: Can They Reach These Targets?

ALLO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Allogene Therapeutics

Off-the-Shelf T-Cell Therapies

Key Moves and Strategic Shifts

What Makes Allogene Different?

Tracking the Financial Progress

Bottom Line

ALLO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Allogene Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALLO

What is the current price of Allogene Therapeutics?

What is the 52-week range for Allogene Therapeutics?

How much debt does Allogene Therapeutics have?

How much cash does Allogene Therapeutics have on hand?

What is Allogene Therapeutics’s dividend yield?

Premium Investing Services